Abstract:Introduction Over 80 000 patients are diagnosed with bladder cancer (BC) yearly in the United States, approximately 25% of which are women. There are unique quality of life (QoL), reproductive, and sexual health considerations when treating women with both muscle- and non-muscle invasive BC (MIBC and NMIBC). While there has been increased understanding of female sexual dysfunction (FSD) in our cystectomy population, there is very little published on FSD in women receiving bladder sparing treatments. Objective To assess the sexual health of female bladder cancer (MIBC and NMIBC) patients receiving bladder sparing therapies through validated survey and patient interview. Methods We performed a retrospective analysis of our institutional bladder cancer database to identify female patients >18 years old with diagnosis of NMIBC or MIBC who had not undergone cystectomy from 2012 to present. All identified patients were invited to participate in a quantitative survey and structured qualitative interview. The survey consisted of the female sexual function index (FSFI), sexual health questions from the EORTC NMIBC-C24 (omitting "male only" questions), and additional selected variables including history of menopause, total or partial hysterectomy, and pelvic radiation. Patients answered survey questions by email or phone and recorded interviews were transcribed. Descriptive analysis, Fisher's exact, and Kruskal-Wallis Test were performed to assess variation in sexual function. Results Of the patients within our cohort who met the inclusion criteria (n = 44), 19 were successfully reached by phone with 18 agreeing to participate in the interview. Patient demographics, medical history, and disease characteristics are displayed in Table 1. Of those interviewed, 5/18 (27.7%) were sexually active. The median (min-max) age of sexually active participants was significantly younger 57 (49-65) years compared to those not sexually active, 75 (60-88) years. There were no other significant differences between the two groups. Of the total participants, 77.8% were white and 50% married. Only one patient had not undergone menopause and 77.8% had a history of total or partial hysterectomy. The majority of the patients met criteria for the American Urologic Association (AUA) high risk category, none were low-risk. The median time since diagnosis was 61 (7-145) months with a median of 13.5 (0-57) BCG treatments total. Two patients have MIBC and were treated with trimodal therapy. Of the sexually active, 1/5 (20%) had FSD based on the FSFI, with scores lowest in desire, arousal, and satisfaction. No sexually active patients endorsed fear of contaminating their partner (Table 2). The majority of patients did not feel that the diagnosis or treatment of BC affected their sexual life, Fig. 1 displays representative patient comments. Conclusions This is the largest quantitative and qualitative study aiming to understand FSD in BC patients who have not undergone cystectomy. Treatment for BC can be burdensome to patients due to years of treatment regimens and surveillance. It is important to understand the unique perspective of women survivorship to provide supportive intervention and counseling. Although limited by small sample size, it appears that FSD is low in patients receiving bladder sparing treatments. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Ferring Pharmaceuticals Inc and Ciox Health, Cg oncology, Engene pharmaceuticals, Photocure, Blue Earth Diagnostics.

Female cancer survivors: sexual function, psychological distress, and remaining fertility

Fertility Issues in Cancer Survivorship

(116) Subjective And Genital Sexual Response In Female Breast Cancer Survivors: Results From A Psychophysiology Study

Fertility under uncertainty: exploring differences in fertility-related concerns and psychosocial aspects between breast cancer survivors and non-cancer infertile women

Perceptions of Infertility and Reproductive Concerns in Adolescent and Young Adult Female Cancer Survivors

Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index

Quality of life and fertility preservation counseling for women with gynecological cancer: an integrated psychological and clinical perspective

Psychological issues in cancer survivorship

P–088 Sexual functioning is impaired in cancer survivors after cancer therapy

Sexual Health in Pre-menopausal Breast Cancer Survivors

Health-related quality of life, sexual function, psychological health, reproductive concerns and fertility outcome in young women treated with fertility-sparing surgery for ovarian tumors - A prospective longitudinal multicentre study

Interventions to Improve Sexual Health in Women Living with and Surviving Cancer: Review and Recommendations

Reproductive Function and Outcomes in Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Review.

Gynecologic cancer survivor preferences for provider communication regarding sexual health after treatment: a qualitative study

Sexual dysfunction among early-onset colorectal cancer survivors: Sex-specific correlates of sexual health discussions between patients and providers

Quality of life and sexuality of patients after treatment for gynaecological malignancies: results of a prospective study in 55 patients

Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors.

Addressing decisional conflict about fertility preservation: helping young female cancer survivors’ family planning decisions

(106) Exploring Female Bladder Cancer Survivorship: Patient Perspectives On Sexual Health Challenges And Resilience When Receiving Bladder Sparing Therapies

Fear of cancer progression and the quality of sexual life of female cancer patients in Romania

Fertility concerns and treatment decision-making among national sample of young women with breast cancer